Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250318-00106
Z Sun, Y Xiao
Transabdominal and transanal endoscopic approaches have become mainstream in colorectal surgery. With the substantial improvement in survival outcomes for colorectal cancer patients, a growing number of colorectal surgeons are increasingly focusing on enhancing postoperative quality of life, prioritizing functional preservation, especially the intraoperative preservation of pelvic autonomic nerves. Recently, with the gradual deepening of artificial intelligence (AI) applications in the medical field, colorectal surgeons have begun exploring its implementation in colorectal surgery. Current achievements primarily involve the identification and protection of nerves and organs. However, most AI applications remain at preclinical exploration stages, limiting their clinical application. Furthermore, AI faces challenges in recognizing blood vessels with significant deformation and movement. Thus, the precise real-time navigation and protection of blood vessels during surgery have yet to be achieved. Therefore, future developments in this field should focus on resolving issues such as non-rigid registration, real-time calibration etc., thereby deepening the application of AI in functional preservation and surgical safety assurance during laparoscopic colorectal surgery.
{"title":"[Artificial intelligence empowers functional preservation and safety guarantee in laparoscopic colorectal surgery].","authors":"Z Sun, Y Xiao","doi":"10.3760/cma.j.cn441530-20250318-00106","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20250318-00106","url":null,"abstract":"<p><p>Transabdominal and transanal endoscopic approaches have become mainstream in colorectal surgery. With the substantial improvement in survival outcomes for colorectal cancer patients, a growing number of colorectal surgeons are increasingly focusing on enhancing postoperative quality of life, prioritizing functional preservation, especially the intraoperative preservation of pelvic autonomic nerves. Recently, with the gradual deepening of artificial intelligence (AI) applications in the medical field, colorectal surgeons have begun exploring its implementation in colorectal surgery. Current achievements primarily involve the identification and protection of nerves and organs. However, most AI applications remain at preclinical exploration stages, limiting their clinical application. Furthermore, AI faces challenges in recognizing blood vessels with significant deformation and movement. Thus, the precise real-time navigation and protection of blood vessels during surgery have yet to be achieved. Therefore, future developments in this field should focus on resolving issues such as non-rigid registration, real-time calibration etc., thereby deepening the application of AI in functional preservation and surgical safety assurance during laparoscopic colorectal surgery.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"615-618"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20240901-00300
R Hou, G B Li, X Y Qiu, X Zhang, G L Lin
Objective: To explore the application of the camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer. Methods: A retrospective study with historical controls was conducted on patients with non-metastatic mid to low rectal cancer which received laparoscopic total mesorectal excision at Peking Union Medical College Hospital from January 2019 to June 2024. The experimental group (2021.7-2024.6) utilized the camera inversion technique (rotating the lens 180° to position the bevel upward and switching the system to reverse display mode for improved visualization and operative angles) during key surgical steps (such as intraoperative mobilization of the mid-to-lower rectum and anastomosis), while the control group (2019.1-2021.6) did not. Clinical data and surgical videos were collected to analyze indicators like operative time, blood loss, mesorectal integrity, surgical complications, and postoperative hospital stay. Results: A total of 624 patients with non-metastatic mid to low rectal cancer were included, including 412 males and 212 females, with an average age of 59.8 years and an average tumor distance of 5.6 cm from the anal verge. The experimental group comprised 301 patients, while the control group had 323 patients.The proportion of abdominal ISR (intersphincteric resection) was significantly higher in the experimental group [19.3% (58/301) vs. 10.2%(33/323), χ2=10.140, P=0.001], with a reduction in operative time [(161.8±67.8) minutes vs. (150.2±68.5) minutes, t=2.134, P=0.033] and a decrease in postoperative hospital stay [(7.8±2.1) days vs. (8.3±3.4) days, t=2.003, P=0.046]. The experimental group also demonstrated advantages in intraoperative blood loss, mesorectal integrity rate, and postoperative complications such as urinary retention, though these differences were not statistically significant (all P>0.05). Conclusion: In laparoscopic surgery for mid to low rectal cancer, using camera inversion technique during distal rectum dissection and transanal anastomosis can provide better surgical field exposure, facilitate precise operations within the correct anatomical plane, and minimize collateral damage. The camera inversion technique is safe and effective.
{"title":"[Camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer].","authors":"R Hou, G B Li, X Y Qiu, X Zhang, G L Lin","doi":"10.3760/cma.j.cn441530-20240901-00300","DOIUrl":"10.3760/cma.j.cn441530-20240901-00300","url":null,"abstract":"<p><p><b>Objective:</b> To explore the application of the camera inversion technique in laparoscopic sphincter-preserving surgery for mid to low rectal cancer. <b>Methods:</b> A retrospective study with historical controls was conducted on patients with non-metastatic mid to low rectal cancer which received laparoscopic total mesorectal excision at Peking Union Medical College Hospital from January 2019 to June 2024. The experimental group (2021.7-2024.6) utilized the camera inversion technique (rotating the lens 180° to position the bevel upward and switching the system to reverse display mode for improved visualization and operative angles) during key surgical steps (such as intraoperative mobilization of the mid-to-lower rectum and anastomosis), while the control group (2019.1-2021.6) did not. Clinical data and surgical videos were collected to analyze indicators like operative time, blood loss, mesorectal integrity, surgical complications, and postoperative hospital stay. <b>Results:</b> A total of 624 patients with non-metastatic mid to low rectal cancer were included, including 412 males and 212 females, with an average age of 59.8 years and an average tumor distance of 5.6 cm from the anal verge. The experimental group comprised 301 patients, while the control group had 323 patients.The proportion of abdominal ISR (intersphincteric resection) was significantly higher in the experimental group [19.3% (58/301) vs. 10.2%(33/323), χ<sup>2</sup>=10.140, <i>P</i>=0.001], with a reduction in operative time [(161.8±67.8) minutes vs. (150.2±68.5) minutes, <i>t</i>=2.134, <i>P</i>=0.033] and a decrease in postoperative hospital stay [(7.8±2.1) days vs. (8.3±3.4) days, <i>t</i>=2.003, <i>P</i>=0.046]. The experimental group also demonstrated advantages in intraoperative blood loss, mesorectal integrity rate, and postoperative complications such as urinary retention, though these differences were not statistically significant (all <i>P</i>>0.05). <b>Conclusion:</b> In laparoscopic surgery for mid to low rectal cancer, using camera inversion technique during distal rectum dissection and transanal anastomosis can provide better surgical field exposure, facilitate precise operations within the correct anatomical plane, and minimize collateral damage. The camera inversion technique is safe and effective.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"679-683"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250317-00105
Y C Guo, H X Zhao, Q Wang
Low anterior resection syndrome (LARS) is a series of symptoms of intestinal dysfunction, and its research is mainly focused on patients with low rectal surgery. However, with the deepening understanding of postoperative LARS, surgeons found that LARS not only exists among patients who have undergone low anterior resection of rectum, but also plagues a considerable number of patients who have undergone non-rectal (mainly colon) surgeries. This article aims to elaborate on the incidence and treatment of LARS after colon surgery. Through a comprehensive analysis of relevant studies, it is found that the incidence of LARS after colon surgery is approximately 20%-30%, and the incidence is relatively higher in patients undergoing right hemicolectomy. Its pathogenesis is related to multiple factors, including surgical methods, resection range, changes in intestinal flora, patient age, gender, and underlying diseases. Treatment methods include conservative treatments such as dietary adjustment, drug therapy, transanal irrigation, and rehabilitation training. Single treatment methods have limited effect, while comprehensive treatment can effectively improve patients' symptoms and quality of life. The current LARS scoring system has not been effectively verified in the application after colon cancer surgery, and it is necessary to develop a more targeted scoring system.
{"title":"[Pathogenesis, risk factors and treatment of low anterior resection syndrome after colon surgery].","authors":"Y C Guo, H X Zhao, Q Wang","doi":"10.3760/cma.j.cn441530-20250317-00105","DOIUrl":"10.3760/cma.j.cn441530-20250317-00105","url":null,"abstract":"<p><p>Low anterior resection syndrome (LARS) is a series of symptoms of intestinal dysfunction, and its research is mainly focused on patients with low rectal surgery. However, with the deepening understanding of postoperative LARS, surgeons found that LARS not only exists among patients who have undergone low anterior resection of rectum, but also plagues a considerable number of patients who have undergone non-rectal (mainly colon) surgeries. This article aims to elaborate on the incidence and treatment of LARS after colon surgery. Through a comprehensive analysis of relevant studies, it is found that the incidence of LARS after colon surgery is approximately 20%-30%, and the incidence is relatively higher in patients undergoing right hemicolectomy. Its pathogenesis is related to multiple factors, including surgical methods, resection range, changes in intestinal flora, patient age, gender, and underlying diseases. Treatment methods include conservative treatments such as dietary adjustment, drug therapy, transanal irrigation, and rehabilitation training. Single treatment methods have limited effect, while comprehensive treatment can effectively improve patients' symptoms and quality of life. The current LARS scoring system has not been effectively verified in the application after colon cancer surgery, and it is necessary to develop a more targeted scoring system.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"633-638"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250310-00095
J Q Kang, Z Zhang
With the advancement of rectal cancer surgery, low anterior resection syndrome (LARS) has emerged as a significant issue impacting the postoperative quality of life for patients. Anorectal manometry (ARM), an essential diagnostic tool, possesses principles and methodologies that are crucial for assessing anorectal function. In the context of LARS diagnosis, ARM plays a pivotal role by providing objective evidence for clinical evaluations. Concurrently, the implications and efficacy of this technology in treatment are gaining increasing attention. Nonetheless, several challenges remain regarding its current application. Through an analysis of existing research, this article aims to elucidate the value of ARM in both the diagnosis and treatment of LARS, with the ultimate goal of enhancing the diagnostic and therapeutic approaches to LARS and improving patients' quality of life.
{"title":"[Application of anorectal manometry in diagnosis and treatment of low anterior resection syndrome].","authors":"J Q Kang, Z Zhang","doi":"10.3760/cma.j.cn441530-20250310-00095","DOIUrl":"10.3760/cma.j.cn441530-20250310-00095","url":null,"abstract":"<p><p>With the advancement of rectal cancer surgery, low anterior resection syndrome (LARS) has emerged as a significant issue impacting the postoperative quality of life for patients. Anorectal manometry (ARM), an essential diagnostic tool, possesses principles and methodologies that are crucial for assessing anorectal function. In the context of LARS diagnosis, ARM plays a pivotal role by providing objective evidence for clinical evaluations. Concurrently, the implications and efficacy of this technology in treatment are gaining increasing attention. Nonetheless, several challenges remain regarding its current application. Through an analysis of existing research, this article aims to elucidate the value of ARM in both the diagnosis and treatment of LARS, with the ultimate goal of enhancing the diagnostic and therapeutic approaches to LARS and improving patients' quality of life.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"639-643"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250410-00153
With the development of surgical techniques, adjuvant therapy and neoadjuvant therapy, the survival time of rectal cancer patients after surgery has been significantly improved, but organ dysfunction is still an important problem affecting the quality of life of patients after surgery. With the continuous deepening of clinical research and practice and the updating of relevant theories, more detailed and reliable evidence-based medical evidence has been accumulated in the field of pelvic organ function protection in rectal cancer surgery, and has been continuously verified in the clinical real world at home and abroad. In order to further improve the awareness of domestic physicians on the protection of organ function during the treatment of rectal cancer, standardize the evaluation methods and surgical methods, reduce the incidence of organ dysfunction, and thus improve the quality of life of patients, Society of Colon & Rectal Surgeons of Chinese College of Surgeons of Chinese Medical Doctor Association, Section of Colorectal Surgery of Branch of Surgery of Chinese Medical Association, National Health Commission Capacity Building and Continuing Education Center Colorectal Surgery Committee, and Colorectal and Anal Function Surgeons Committee of China Sexology Association organized the discussion among relevant experts. On the basis of the 2021 edition of the Chinese Expert Consensus on the Protection of Pelvic Organ Function in Rectal Cancer Surgery, the recent evidence-based medical evidence was analyzed and summarized, and the definition, risk factors, evaluation methods, prevention and other issues of organ dysfunction after rectal cancer surgery were analyzed with reference to relevant domestic and foreign studies and combined with clinical practice. Proposed the diagnosis, evaluation and treatment of pelvic organ dysfunction in rectal cancer surgery, and finally formed the "Chinese expert Consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)".
{"title":"[Expert consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)].","authors":"","doi":"10.3760/cma.j.cn441530-20250410-00153","DOIUrl":"10.3760/cma.j.cn441530-20250410-00153","url":null,"abstract":"<p><p>With the development of surgical techniques, adjuvant therapy and neoadjuvant therapy, the survival time of rectal cancer patients after surgery has been significantly improved, but organ dysfunction is still an important problem affecting the quality of life of patients after surgery. With the continuous deepening of clinical research and practice and the updating of relevant theories, more detailed and reliable evidence-based medical evidence has been accumulated in the field of pelvic organ function protection in rectal cancer surgery, and has been continuously verified in the clinical real world at home and abroad. In order to further improve the awareness of domestic physicians on the protection of organ function during the treatment of rectal cancer, standardize the evaluation methods and surgical methods, reduce the incidence of organ dysfunction, and thus improve the quality of life of patients, Society of Colon & Rectal Surgeons of Chinese College of Surgeons of Chinese Medical Doctor Association, Section of Colorectal Surgery of Branch of Surgery of Chinese Medical Association, National Health Commission Capacity Building and Continuing Education Center Colorectal Surgery Committee, and Colorectal and Anal Function Surgeons Committee of China Sexology Association organized the discussion among relevant experts. On the basis of the 2021 edition of the Chinese Expert Consensus on the Protection of Pelvic Organ Function in Rectal Cancer Surgery, the recent evidence-based medical evidence was analyzed and summarized, and the definition, risk factors, evaluation methods, prevention and other issues of organ dysfunction after rectal cancer surgery were analyzed with reference to relevant domestic and foreign studies and combined with clinical practice. Proposed the diagnosis, evaluation and treatment of pelvic organ dysfunction in rectal cancer surgery, and finally formed the \"Chinese expert Consensus on the protection of pelvic organ function in rectal cancer surgery (version 2025)\".</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"575-586"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20241209-00400
H P Hong, A Huang, J Y Shi, J Gu
Objective: To investigate the differences in clinical characteristics and prognosis between early- and late-onset rectal cancer (EORC and LORC, respectively), and to analyze the adverse factors affecting outcomes in EORC patients. Methods: This retrospective cohort and propensity score matching (PSM) study examined 904 rectal cancer patients who underwent radical resection at Peking University Shougang Hospital between 2017 and 2022. Prior to comparison, patients in the EORC group (<50 years old) and LORC group (≥50 years old) were matched at a 1:2 ratio to control for the following confounders: sex; neoadjuvant therapy; T, N, and M stage; and adjuvant treatment. Cox regression was used to identify independent risk factors for poor overall and progression-free survival (OS and PFS, respectively). Restricted cubic splines were used to analyze the association between age and clinical outcome. Results: A total of 199 EORC and 705 LORC patients were included for analysis. Prior to PSM, the proportions of patients with stage T4 [27.6%(55/199) vs.12.9%(91/705),χ2=30.12,P<0.001] and M1 disease [24.6%(49/199) vs. 15.7% (111/705),χ2=8.40,P=0.004], and the proportions of patients who received neoadjuvant [79.9% (159/199) vs. 62.3%(439/705), χ2=21.54, P<0.001] and adjuvant therapy [62.8%(125/199) vs. 50.8% (358/705), χ2=9.03, P=0.003] were significantly higher in the EORC group. Mean OS (57.8 vs. 51.9 months; P=0.011) and PFS (53.6 vs. 44.5 months; P=0.001) were also significantly longer in the LORC group. However, after PSM, the intergroup differences in OS and PFS were not significant (P=0.450 and 0.180, respectively). Multivariate Cox regression in the EORC cohort identified carcinoembryonic antigen concentration ≥5 μg/L [hazard ratio (HR), 3.79; 95% confidence interval (CI), 1.34-10.69; P=0.012] and presence of perineural invasion (HR, 7.27; 95%CI, 1.77-29.88; P=0.006) as independent risk factors for overall mortality; the only independent risk factor for cancer progression was carcinoembryonic antigen concentration ≥5 μg/L (HR, 2.56; 95%CI, 1.06-6.17; P=0.037). Restricted cubic spline analysis showed a U-shaped relationship between age and clinical outcome. After PSM, OS and PFS did not show a significant association with age in the < 60 years old group. Conclusion: Compared with LORC, EORC is more likely to be diagnosed at a later stage and has a worse outcome. Early diagnosis and timely treatment improve outcome in EORC patients.
{"title":"[Comparative study of clinical characteristics and prognosis between early- and late-onset rectal cancer].","authors":"H P Hong, A Huang, J Y Shi, J Gu","doi":"10.3760/cma.j.cn441530-20241209-00400","DOIUrl":"10.3760/cma.j.cn441530-20241209-00400","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the differences in clinical characteristics and prognosis between early- and late-onset rectal cancer (EORC and LORC, respectively), and to analyze the adverse factors affecting outcomes in EORC patients. <b>Methods:</b> This retrospective cohort and propensity score matching (PSM) study examined 904 rectal cancer patients who underwent radical resection at Peking University Shougang Hospital between 2017 and 2022. Prior to comparison, patients in the EORC group (<50 years old) and LORC group (≥50 years old) were matched at a 1:2 ratio to control for the following confounders: sex; neoadjuvant therapy; T, N, and M stage; and adjuvant treatment. Cox regression was used to identify independent risk factors for poor overall and progression-free survival (OS and PFS, respectively). Restricted cubic splines were used to analyze the association between age and clinical outcome. <b>Results:</b> A total of 199 EORC and 705 LORC patients were included for analysis. Prior to PSM, the proportions of patients with stage T4 [27.6%(55/199) vs.12.9%(91/705),χ<sup>2</sup>=30.12,<i>P</i><0.001] and M1 disease [24.6%(49/199) vs. 15.7% (111/705),χ<sup>2</sup>=8.40,<i>P</i>=0.004], and the proportions of patients who received neoadjuvant [79.9% (159/199) vs. 62.3%(439/705), χ<sup>2</sup>=21.54, <i>P</i><0.001] and adjuvant therapy [62.8%(125/199) vs. 50.8% (358/705), χ<sup>2</sup>=9.03, <i>P</i>=0.003] were significantly higher in the EORC group. Mean OS (57.8 vs. 51.9 months; <i>P</i>=0.011) and PFS (53.6 vs. 44.5 months; <i>P</i>=0.001) were also significantly longer in the LORC group. However, after PSM, the intergroup differences in OS and PFS were not significant (<i>P</i>=0.450 and 0.180, respectively). Multivariate Cox regression in the EORC cohort identified carcinoembryonic antigen concentration ≥5 μg/L [hazard ratio (HR), 3.79; 95% confidence interval (CI), 1.34-10.69; <i>P</i>=0.012] and presence of perineural invasion (HR, 7.27; 95%CI, 1.77-29.88; <i>P</i>=0.006) as independent risk factors for overall mortality; the only independent risk factor for cancer progression was carcinoembryonic antigen concentration ≥5 μg/L (HR, 2.56; 95%CI, 1.06-6.17; <i>P</i>=0.037). Restricted cubic spline analysis showed a U-shaped relationship between age and clinical outcome. After PSM, OS and PFS did not show a significant association with age in the < 60 years old group. <b>Conclusion:</b> Compared with LORC, EORC is more likely to be diagnosed at a later stage and has a worse outcome. Early diagnosis and timely treatment improve outcome in EORC patients.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"662-671"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20241114-00373
Y Wang, F Tian, C Q Jing
Neoadjuvant chemoradiotherapy (NACRT) is the standard treatment for locally advanced rectal cancer (LARC), yet the pathological complete response (pCR) rates remain suboptimal. The introduction of immunotherapy has opened new avenues for LARC management, particularly in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status. In this subset, anti-programmed cell death protein-1 (PD-1) monoclonal antibodies demonstrate marked efficacy, achieving high rates of clinical complete response (cCR) and pCR, thereby facilitating non-operative watch-and-wait (W&W) strategies. However, long-term outcomes and large-scale validation are still awaited. Conversely, in patients with LARC who have proficient mismatch repair (pMMR) or microsatellite stability (MSS), PD-1 inhibition alone shows limited benefit. Current research thus focuses on combinatorial approaches. Combining immunotherapy with chemoradiotherapy has shown promise in improving pCR rates in pMMR/MSS LARC, without significantly exacerbating severe adverse events. However, the discordance between post-treatment imaging assessments and pathological findings complicates clinical decision-making. Future directions include optimizing immune checkpoint inhibitor (ICI) regimens for pMMR/MSS LARC, with ongoing investigations into dual immunotherapy and anti-angiogenic synergism. Additionally, biomarker discovery, which is leveraging multi-omics and artificial intelligence (AI), will be pivotal in achieving precision therapy that balances short-term efficacy with long-term survival benefits.
{"title":"[Progress in neoadjuvant immunotherapy for locally advanced rectal cancer].","authors":"Y Wang, F Tian, C Q Jing","doi":"10.3760/cma.j.cn441530-20241114-00373","DOIUrl":"10.3760/cma.j.cn441530-20241114-00373","url":null,"abstract":"<p><p>Neoadjuvant chemoradiotherapy (NACRT) is the standard treatment for locally advanced rectal cancer (LARC), yet the pathological complete response (pCR) rates remain suboptimal. The introduction of immunotherapy has opened new avenues for LARC management, particularly in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status. In this subset, anti-programmed cell death protein-1 (PD-1) monoclonal antibodies demonstrate marked efficacy, achieving high rates of clinical complete response (cCR) and pCR, thereby facilitating non-operative watch-and-wait (W&W) strategies. However, long-term outcomes and large-scale validation are still awaited. Conversely, in patients with LARC who have proficient mismatch repair (pMMR) or microsatellite stability (MSS), PD-1 inhibition alone shows limited benefit. Current research thus focuses on combinatorial approaches. Combining immunotherapy with chemoradiotherapy has shown promise in improving pCR rates in pMMR/MSS LARC, without significantly exacerbating severe adverse events. However, the discordance between post-treatment imaging assessments and pathological findings complicates clinical decision-making. Future directions include optimizing immune checkpoint inhibitor (ICI) regimens for pMMR/MSS LARC, with ongoing investigations into dual immunotherapy and anti-angiogenic synergism. Additionally, biomarker discovery, which is leveraging multi-omics and artificial intelligence (AI), will be pivotal in achieving precision therapy that balances short-term efficacy with long-term survival benefits.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"700-706"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250409-00145
C Wang, F Liu, S Hou, Z L Shen, M J Yin, X D Yang, K W Jiang, Q W Xie, B Liang, K Shen, Z D Gao, Y J Ye
<p><p><b>Objective:</b> To compare bowel function 12 months after surgery between side-to-end anastomosis (SEA) and end-to-end anastomosis (EEA) groups of patients who had undergone rectal cancer resection. <b>Methods:</b> This single-center, prospective, open-label, phase III randomized controlled trial was approved by the Ethics Committee of Peking University People's Hospital (2018PHB040-01) and registered at ClinicalTrials. org (NCT03669237). Inclusion criteria were as follows: (1) histologically confirmed rectal adenocarcinoma; (2) tumor located 0 to 12 cm from the anal verge; (3) age≥18 years; and (4) planned R0 resection with primary reconstruction. Exclusion criteria included: (1) emergency surgery; (2) cognitive impairment; (3) non-primary anastomosis; (4) history of left-sided colonic or anorectal surgery; and (5) preexisting chronic defecation dysfunction. Eligible rectal cancer patients scheduled for elective sphincter-preserving surgery at Peking University People's Hospital were prospectively enrolled between October 2018 and March 2021 and randomly assigned to either the EEA group or the SEA group via computer-generated numbers prior to entering the operating room. All patients underwent standard radical tumor resection. Bowel function was evaluated by the low anterior resection syndrome (LARS) questionnaire. It consists of five single-choice questions and yields a total score ranging from 0 to 42. Defecation function is categorized into three levels: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). The primary endpoint was the LARS score 12 months after surgery. Secondary endpoints included LARS scores from 1 to 11 months and during long-term follow-up(>12 months). The final follow-up was completed in July 2022. All randomized patients were included in the intention-to-treat set (ITTS). The full analysis set (FAS) was defined as ITTS patients with valid outcome data. All primary statistical analyses were performed in the FAS, and results were further compared in the per-protocol set (PPS) based on the actual treatment received. <b>Results:</b> A total of 323 patients underwent eligibility assessment, of whom 71 did not meet the inclusion criteria and 52 declined to participate. Ultimately, 200 patients were randomized. Median age was 64 years and 85 were women. The SEA and EEA groups comprised 102 and 98 patients, respectively. A total of 181 patients (90.5%) were included in the FAS, and 170 (85.0%) were included in the PPS. Among these, the 12-month LARS score was evaluated in 178 patients (98.3%) in the FAS and in 167 (98.2%) in the PPS. Median LARS score at 1-12 months were significantly lower in the SEA group in both the FAS dataset [12 months:8 (interquartile range [IQR], 0-22) vs. 14 (IQR, 8-29); <i>Z</i>=2.687, <i>P</i>=0.007] and the PPS dataset [12 months: 8 (IQR, 0-22) vs. 14 (IQR, 6-29); <i>Z</i>=2.543, <i>P</i>=0.011]. During long-term follow-up, the median LARS score was also significa
目的:比较侧端吻合术(SEA)组和端端吻合术(EEA)组直肠癌切除术患者术后12个月的肠功能。方法:该单中心、前瞻性、开放标签、III期随机对照试验经北京大学人民医院伦理委员会批准(2018PHB040-01),并在ClinicalTrials注册。org (NCT03669237)。纳入标准如下:(1)经组织学证实的直肠腺癌;(2)肿瘤位于距肛门边缘0 ~ 12cm处;(3)年龄≥18岁;(4)计划R0切除并一期重建。排除标准包括:(1)急诊手术;(2)认知障碍;(3)非初级吻合;(4)左侧结肠或肛肠手术史;(5)既往慢性排便功能障碍。前瞻性纳入2018年10月至2021年3月在北京大学人民医院择期行保留括约肌手术的符合条件的直肠癌患者,并在进入手术室前通过计算机生成的数字随机分配到EEA组或SEA组。所有患者均行标准根治性肿瘤切除术。通过前低位切除综合征(LARS)问卷评估肠功能。它由五个单项选择题组成,总分在0到42分之间。排便功能分为无LARS(0-20分)、轻度LARS(21-29分)和重度LARS(30-42分)三个级别。主要终点是术后12个月的LARS评分。次要终点包括1 - 11个月和长期随访期间(bb0 - 12个月)的LARS评分。最后的后续工作于2022年7月完成。所有随机患者均纳入意向治疗组(ITTS)。完整分析集(FAS)定义为具有有效结局数据的ITTS患者。所有主要统计分析均在FAS中进行,并根据实际接受的治疗在每个方案集(PPS)中进一步比较结果。结果:共有323例患者接受了资格评估,其中71例不符合纳入标准,52例拒绝参与。最终,200名患者被随机分配。平均年龄为64岁,女性为85岁。SEA组102例,EEA组98例。FAS组181例(90.5%),PPS组170例(85.0%)。其中FAS组178例(98.3%),PPS组167例(98.2%)进行了12个月LARS评分。在FAS数据集中,SEA组在1-12个月时的LARS中位数评分显著低于对照组[12个月:8(四分位间距[IQR], 0-22)比14 (IQR, 8-29);Z=2.687, P=0.007]和PPS数据集[12个月:8 (IQR, 0-22) vs. 14 (IQR, 6-29);Z = 2.543, P = 0.011)。在长期随访期间,FAS数据集中SEA组的LARS中位评分也显著降低[2 (IQR, 0-4) vs. 11 (IQR, 2-23);Z=2.968, P=0.003]和PPS数据集[2 (IQR, 0-14) vs. 11 (2,27)];Z = 2.687, P = 0.007)。结论:与EEA组相比,SEA组术后1年及长期随访期间的肠功能优于EEA组。
{"title":"[Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial].","authors":"C Wang, F Liu, S Hou, Z L Shen, M J Yin, X D Yang, K W Jiang, Q W Xie, B Liang, K Shen, Z D Gao, Y J Ye","doi":"10.3760/cma.j.cn441530-20250409-00145","DOIUrl":"10.3760/cma.j.cn441530-20250409-00145","url":null,"abstract":"<p><p><b>Objective:</b> To compare bowel function 12 months after surgery between side-to-end anastomosis (SEA) and end-to-end anastomosis (EEA) groups of patients who had undergone rectal cancer resection. <b>Methods:</b> This single-center, prospective, open-label, phase III randomized controlled trial was approved by the Ethics Committee of Peking University People's Hospital (2018PHB040-01) and registered at ClinicalTrials. org (NCT03669237). Inclusion criteria were as follows: (1) histologically confirmed rectal adenocarcinoma; (2) tumor located 0 to 12 cm from the anal verge; (3) age≥18 years; and (4) planned R0 resection with primary reconstruction. Exclusion criteria included: (1) emergency surgery; (2) cognitive impairment; (3) non-primary anastomosis; (4) history of left-sided colonic or anorectal surgery; and (5) preexisting chronic defecation dysfunction. Eligible rectal cancer patients scheduled for elective sphincter-preserving surgery at Peking University People's Hospital were prospectively enrolled between October 2018 and March 2021 and randomly assigned to either the EEA group or the SEA group via computer-generated numbers prior to entering the operating room. All patients underwent standard radical tumor resection. Bowel function was evaluated by the low anterior resection syndrome (LARS) questionnaire. It consists of five single-choice questions and yields a total score ranging from 0 to 42. Defecation function is categorized into three levels: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). The primary endpoint was the LARS score 12 months after surgery. Secondary endpoints included LARS scores from 1 to 11 months and during long-term follow-up(>12 months). The final follow-up was completed in July 2022. All randomized patients were included in the intention-to-treat set (ITTS). The full analysis set (FAS) was defined as ITTS patients with valid outcome data. All primary statistical analyses were performed in the FAS, and results were further compared in the per-protocol set (PPS) based on the actual treatment received. <b>Results:</b> A total of 323 patients underwent eligibility assessment, of whom 71 did not meet the inclusion criteria and 52 declined to participate. Ultimately, 200 patients were randomized. Median age was 64 years and 85 were women. The SEA and EEA groups comprised 102 and 98 patients, respectively. A total of 181 patients (90.5%) were included in the FAS, and 170 (85.0%) were included in the PPS. Among these, the 12-month LARS score was evaluated in 178 patients (98.3%) in the FAS and in 167 (98.2%) in the PPS. Median LARS score at 1-12 months were significantly lower in the SEA group in both the FAS dataset [12 months:8 (interquartile range [IQR], 0-22) vs. 14 (IQR, 8-29); <i>Z</i>=2.687, <i>P</i>=0.007] and the PPS dataset [12 months: 8 (IQR, 0-22) vs. 14 (IQR, 6-29); <i>Z</i>=2.543, <i>P</i>=0.011]. During long-term follow-up, the median LARS score was also significa","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"644-652"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250310-00093
P Lai, Z He
Gastrointestinal dysfunction is a common and significant complication in colorectal surgical practice, which is associated with gut microbiota dysbiosis caused by various perioperative interventions. Currently, enhanced recovery after surgery (ERAS) protocols have been increasingly adopted in clinical practice, greatly accelerating the recovery of postoperative intestinal function. However, there are still no effective interventions in the ERAS protocols to target surgery-induced gut microbiota dysbiosis. Probiotics, as a key treatment method targeting the gut microbiota, can stimulate intestinal motility, inhibit the colonization of pathogenic bacteria, enhance intestinal barrier function, among other effects. Based on these effects of probiotics, they are expected to resolve the neglected gut microbiota dysbiosis, further accelerating the postoperative recovery of intestinal function after colorectal surgery. This article reviews the mechanisms and clinical progress in postoperative bowel functional recovery after colorectal surgery.
胃肠功能障碍是结直肠手术中常见且重要的并发症,它与各种围手术期干预引起的肠道菌群失调有关。目前,临床越来越多地采用ERAS (enhanced recovery after surgery)方案,大大加快了术后肠道功能的恢复。然而,在ERAS方案中仍然没有针对手术引起的肠道菌群失调的有效干预措施。益生菌作为针对肠道菌群的关键治疗手段,具有刺激肠道蠕动、抑制病原菌定植、增强肠道屏障功能等作用。基于益生菌的这些作用,它们有望解决被忽视的肠道菌群失调,进一步加速结肠直肠癌术后肠道功能的恢复。本文就结直肠手术后肠功能恢复的机制及临床进展进行综述。
{"title":"[Probiotics empower postoperative intestinal function recovery after colorectal surgery: mechanisms and clinical progress].","authors":"P Lai, Z He","doi":"10.3760/cma.j.cn441530-20250310-00093","DOIUrl":"10.3760/cma.j.cn441530-20250310-00093","url":null,"abstract":"<p><p>Gastrointestinal dysfunction is a common and significant complication in colorectal surgical practice, which is associated with gut microbiota dysbiosis caused by various perioperative interventions. Currently, enhanced recovery after surgery (ERAS) protocols have been increasingly adopted in clinical practice, greatly accelerating the recovery of postoperative intestinal function. However, there are still no effective interventions in the ERAS protocols to target surgery-induced gut microbiota dysbiosis. Probiotics, as a key treatment method targeting the gut microbiota, can stimulate intestinal motility, inhibit the colonization of pathogenic bacteria, enhance intestinal barrier function, among other effects. Based on these effects of probiotics, they are expected to resolve the neglected gut microbiota dysbiosis, further accelerating the postoperative recovery of intestinal function after colorectal surgery. This article reviews the mechanisms and clinical progress in postoperative bowel functional recovery after colorectal surgery.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"619-626"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-25DOI: 10.3760/cma.j.cn441530-20250306-00087
Z J Guan, W Y Zhang, G Y Wang
The key points of the update of the content related to colorectal cancer and anal cancer in the Chinese Anti-Cancer Association (CACA) Guidelines for Integrative Oncology 2025 Edition (hereinafter referred to as the CACA 2025 Guidelines) include 4 aspects. In terms of epidemiology, the latest data on the incidence and mortality of colorectal cancer in China have been updated, and the recommended screening age has been adjusted. In diagnosis, the application of enhanced MRI examination in diagnosis has been optimized, and the recommendation for peripheral blood microsatellite instability (MSI) detection has been added. In terms of treatment, in surgical treatment, the total mesorectal excision of the right colon, the safety of the Natural Orifice Specimen Extraction Surgery (NOSES) technique, the applicable range of robotic surgery, and the high-level evidence-based medical evidence of transanal total mesorectal excision (taTME) have been newly added, and the principles of surgical treatment have been added as well. In medical treatment, the role of circulating tumor DNA (ctDNA) in treatment decision-making has been supplemented. The application of dual immunotherapy in advanced patients has been recommended, and the application of third-line and subsequent-line treatments in advanced patients has been newly added. The guidelines improved the principle of preoperative neoadjuvant radiotherapy for rectal cancer, changed the indication of short-course radiotherapy, and added a variety of chemoradiotherapy combinations and recommendations for the timing of surgery. In addition, the follow-up programs for colorectal cancer and anal canal cancer are clarified, and nutritional therapy, traditional Chinese medicine rehabilitation therapy and nursing care for sequelae are emphasized, which provide more scientific and comprehensive guidance for the diagnosis and treatment of colorectal cancer and anal canal cancer.
{"title":"[Interpretation of the update points of colorectal and anal cancer in CACA guidelines (2025 edition)].","authors":"Z J Guan, W Y Zhang, G Y Wang","doi":"10.3760/cma.j.cn441530-20250306-00087","DOIUrl":"https://doi.org/10.3760/cma.j.cn441530-20250306-00087","url":null,"abstract":"<p><p>The key points of the update of the content related to colorectal cancer and anal cancer in the Chinese Anti-Cancer Association (CACA) Guidelines for Integrative Oncology 2025 Edition (hereinafter referred to as the CACA 2025 Guidelines) include 4 aspects. In terms of epidemiology, the latest data on the incidence and mortality of colorectal cancer in China have been updated, and the recommended screening age has been adjusted. In diagnosis, the application of enhanced MRI examination in diagnosis has been optimized, and the recommendation for peripheral blood microsatellite instability (MSI) detection has been added. In terms of treatment, in surgical treatment, the total mesorectal excision of the right colon, the safety of the Natural Orifice Specimen Extraction Surgery (NOSES) technique, the applicable range of robotic surgery, and the high-level evidence-based medical evidence of transanal total mesorectal excision (taTME) have been newly added, and the principles of surgical treatment have been added as well. In medical treatment, the role of circulating tumor DNA (ctDNA) in treatment decision-making has been supplemented. The application of dual immunotherapy in advanced patients has been recommended, and the application of third-line and subsequent-line treatments in advanced patients has been newly added. The guidelines improved the principle of preoperative neoadjuvant radiotherapy for rectal cancer, changed the indication of short-course radiotherapy, and added a variety of chemoradiotherapy combinations and recommendations for the timing of surgery. In addition, the follow-up programs for colorectal cancer and anal canal cancer are clarified, and nutritional therapy, traditional Chinese medicine rehabilitation therapy and nursing care for sequelae are emphasized, which provide more scientific and comprehensive guidance for the diagnosis and treatment of colorectal cancer and anal canal cancer.</p>","PeriodicalId":23959,"journal":{"name":"中华胃肠外科杂志","volume":"28 6","pages":"693-699"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}